[{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LCB97","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ligachem Biosciences","amount2":0.69999999999999996,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ligachem Biosciences \/ Ono Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Ligachem Biosciences \/ Ono Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by Ligachem Biosciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Ono will have an exclusive worldwide right to develop, manufacture and commercialize LCB97, a pre-clinical stage antibody-drug conjugate, for solid tumors.

                          Brand Name : LCB97

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 10, 2024

                          Lead Product(s) : LCB97

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Ono Pharmaceutical

                          Deal Size : $700.0 million

                          Deal Type : Licensing Agreement

                          blank